India, a leading manufacturer of generic medicines, is expected to play a key role in the race to develop a COVID-19 vaccine, with several institutes working in parallel
All IndiaReported by Parimal Kumar, Edited by Chandrashekar SrinivasanUpdated: June 29, 2020 11:11 pm IST
COVAXIN, India's first COVID-19 vaccine candidate, was developed in association with ICMR
The British firm has already begun large-scale, mid-stage human trials of the drug developed by researchers at University of Oxford.
Other possible vaccines being tested include one by American firm Moderna, which is scheduled to go into Phase III clinical trials from mid-July.
China's military has been given permission to use a vaccine candidate developed in association with CanSino Biologics. According to Reuters the drug showed some promise in early clinical trials. The Ad5-nCoV is one of the eight vaccine candidates developed by Chinese firms to move into human trials.
Early last month US-based biopharmaceutical firm Gilead Sciences Inc. said a five-day course of its antiviral drug Remdesivir showed a modest benefit to patients with moderate COVID-19 symptoms.
The drug, which is administered intravenously, was the first to show improvement in condition of COVID-19 patients in formal clinical trials, according to news agency Reuters.
As pharma firms scramble to find that big breakthrough, which could mean millions in profits and millions of lives saved, experts have warned that early vaccines may come with limitations on what they can do.
The pandemic has already claimed over five lakh victims worldwide, including 16,475 in India. There are over 1.01 crore confirmed cases, including nearly 5.5 lakh in India - the fourth worst-affected country.
With input from Reuters
https://www.ndtv.com/india-news/cor...idate-set-for-phase-i-ii-human-trials-2254189
All IndiaReported by Parimal Kumar, Edited by Chandrashekar SrinivasanUpdated: June 29, 2020 11:11 pm IST
COVAXIN, India's first COVID-19 vaccine candidate, was developed in association with ICMR
The British firm has already begun large-scale, mid-stage human trials of the drug developed by researchers at University of Oxford.
Other possible vaccines being tested include one by American firm Moderna, which is scheduled to go into Phase III clinical trials from mid-July.
China's military has been given permission to use a vaccine candidate developed in association with CanSino Biologics. According to Reuters the drug showed some promise in early clinical trials. The Ad5-nCoV is one of the eight vaccine candidates developed by Chinese firms to move into human trials.
Early last month US-based biopharmaceutical firm Gilead Sciences Inc. said a five-day course of its antiviral drug Remdesivir showed a modest benefit to patients with moderate COVID-19 symptoms.
The drug, which is administered intravenously, was the first to show improvement in condition of COVID-19 patients in formal clinical trials, according to news agency Reuters.
As pharma firms scramble to find that big breakthrough, which could mean millions in profits and millions of lives saved, experts have warned that early vaccines may come with limitations on what they can do.
The pandemic has already claimed over five lakh victims worldwide, including 16,475 in India. There are over 1.01 crore confirmed cases, including nearly 5.5 lakh in India - the fourth worst-affected country.
With input from Reuters
https://www.ndtv.com/india-news/cor...idate-set-for-phase-i-ii-human-trials-2254189
